Zacks: Brokerages Anticipate Viracta Therapeutics, Inc. (NASDAQ:VIRX) to Post -$0.32 Earnings Per Share

Brokerages predict that Viracta Therapeutics, Inc. (NASDAQ:VIRXGet Rating) will announce earnings per share (EPS) of ($0.32) for the current quarter, Zacks reports. Zero analysts have made estimates for Viracta Therapeutics’ earnings, with estimates ranging from ($0.32) to ($0.31). Viracta Therapeutics reported earnings per share of $0.38 in the same quarter last year, which suggests a negative year-over-year growth rate of 184.2%. The firm is expected to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Viracta Therapeutics will report full year earnings of ($1.44) per share for the current fiscal year, with EPS estimates ranging from ($1.64) to ($1.33). For the next year, analysts anticipate that the business will post earnings of ($1.65) per share, with EPS estimates ranging from ($1.85) to ($1.45). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover Viracta Therapeutics.

Viracta Therapeutics (NASDAQ:VIRXGet Rating) last announced its quarterly earnings data on Wednesday, March 16th. The company reported ($0.31) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.09.

Several equities research analysts have weighed in on VIRX shares. Royal Bank of Canada started coverage on shares of Viracta Therapeutics in a report on Tuesday, February 1st. They issued an “outperform” rating and a $10.00 target price on the stock. Zacks Investment Research raised shares of Viracta Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 13th.

VIRX traded up $0.01 during mid-day trading on Thursday, hitting $3.31. The stock had a trading volume of 5,102 shares, compared to its average volume of 294,095. The business’s fifty day simple moving average is $3.38. The company has a debt-to-equity ratio of 0.05, a current ratio of 11.59 and a quick ratio of 11.59. The firm has a market cap of $124.08 million, a price-to-earnings ratio of -0.53 and a beta of 2.26. Viracta Therapeutics has a 1-year low of $2.18 and a 1-year high of $13.08.

In other news, CEO Ivor Royston sold 14,635 shares of the stock in a transaction on Monday, February 28th. The shares were sold at an average price of $2.78, for a total transaction of $40,685.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 21,028 shares of company stock valued at $58,458 in the last three months. 3.72% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Citigroup Inc. grew its position in Viracta Therapeutics by 109.6% in the third quarter. Citigroup Inc. now owns 4,206 shares of the company’s stock valued at $34,000 after purchasing an additional 2,199 shares in the last quarter. Advisor Group Holdings Inc. bought a new position in Viracta Therapeutics in the third quarter valued at $39,000. Bank of New York Mellon Corp grew its position in Viracta Therapeutics by 9.8% in the third quarter. Bank of New York Mellon Corp now owns 107,938 shares of the company’s stock valued at $866,000 after purchasing an additional 9,643 shares in the last quarter. State Board of Administration of Florida Retirement System bought a new position in Viracta Therapeutics in the third quarter valued at $81,000. Finally, Invesco Ltd. bought a new position in Viracta Therapeutics in the third quarter valued at $94,000. 42.12% of the stock is owned by institutional investors and hedge funds.

Viracta Therapeutics Company Profile (Get Rating)

Viracta Therapeutics, Inc, a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.

Read More

Get a free copy of the Zacks research report on Viracta Therapeutics (VIRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Viracta Therapeutics (NASDAQ:VIRX)

Receive News & Ratings for Viracta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viracta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.